Lancet Regional Health-Americas最新文献

Background: The proportion of people living with HIV (PLWHIV) co-infected with HCV in Mexico was unknown. Our aim was to estimate the seroprevalence of HCV among adults with HIV in Mexico.

Methods: Using a complex-survey design, we collected blood samples and applied structured questionnaires between May 2nd, 2019 and February 17th, 2020 in a nationally, representative sample of adults receiving care for HIV-infection in 24 randomly selected HIV-care centres in 8 socio-demographically regions in Mexico. We tested serum for anti-HCV IgG antibodies and collected data on risky exposures. We estimated the seroprevalence of HCV and associated exposures using regression models and the Taylor linearization method to account for the cluster effect by region and centre.

Findings: We collected blood samples of 2545 participants. Most participants were men (75.8%) with a median age of 37 years. The estimated seroprevalence of HCV is 3.9% (95% CI 3.1%-4.7%). Only 39 of 99 participants (40%) with HCV antibodies had active replication determined by RNA quantification. Seroprevalence of HCV was significantly higher among people with life-time history of imprisonment (9%, 95% CI 4.4%-13.6%), tattoo use (5.9%, 95% CI 3.9%-8%), and lifetime (22.3%, 95% CI 12.1%-32.6%) and recent (49.3%, 95% CI 18.3%-80.3%) injecting-drug use.

Interpretation: Seroprevalence of HCV infection among PLWHIV in Mexico is ten times as high as the seroprevalence for the general population. The national program for HCV elimination focused in PLWHIV should target people that use injecting drugs and living in prisons.

Funding: Abbvie Farmacéuticos, S.A de C.V Mexico through Investigator Initiated Study (2018).

Background: While Indigenous people are overrepresented in Canada's prisons and in the toxic drug supply crisis, we lack data on the harms related to opioids for Indigenous people with experiences of incarceration. We aimed to examine opioid toxicity deaths in Indigenous peoples who experienced incarceration and to compare opioid toxicity mortality rates with rates for people with no incarceration.

Methods: This retrospective cohort study linked correctional data for all people who were incarcerated in provincial correctional facilities and coronial data for all people who died from opioid toxicity in Ontario, Canada between 2015 and 2020. We calculated opioid mortality rates for Indigenous people who experienced incarceration and for people who did not experience incarceration using publicly available population data and calculated age-standardized mortality rates for Indigenous and non-Indigenous people who experienced incarceration compared with people who did not experience incarceration.

Findings: Of 14,885 Indigenous people who experienced incarceration, 2% (N = 242) died from opioid toxicity in custody or post-release, representing 2.9% of all opioid toxicity deaths in Ontario during this period. The crude opioid toxicity mortality rate per 100 person-years was 0.53 for Indigenous females and 0.36 for Indigenous males who experienced incarceration, compared with 0.0060 for females and 0.0132 for males who did not experience incarceration. Rates of opioid toxicity death were highest in the month post-release for Indigenous people who experienced incarceration, at 1.13 per 100 person-years. Standardized for age and compared with people with no incarceration, the mortality ratio was 81.0 (95% CI 62.1-100.0) for Indigenous females who experienced incarceration and 23.6 (95% CI 20.1-27.1) for Indigenous males who experienced incarceration. The SMRs for Indigenous and non-Indigenous females who experienced incarceration were not significantly different, at 81.0 compared with 76.4, and were significantly different for Indigenous and non-Indigenous males who experienced incarceration, at 23.6 compared with 28.5.

Interpretation: This whole-population study identified a substantial and inequitable burden of opioid toxicity death for Indigenous people who experienced incarceration, similar to the burden for non-Indigenous people who experienced incarceration. The large burden is particularly concerning in the context of the overrepresentation of Indigenous people in correctional facilities. Focus is warranted to prevent substance use harms for Indigenous people, including through community- and custody-based interventions to support health.

Funding: Canadian Institutes of Health Research through the Canadian Research Initiative in Substance Misuse (SMN-139150 and REN-181677).

Background: Despite government efforts, tuberculosis (TB) remains a major public health threat in Brazil. In 2023, TB incidence was 39.8 cases per 100,000 population, far above the WHO's target of 6.7 cases per 100,000. Using national-level datasets, we investigated and forecasted the potential impact of proposed public health interventions aimed at reducing TB incidence in Brazil.

Methods: Monthly TB surveillance data (January 2018-December 2023) were collected from Brazilian national reporting systems: SINAN-TB (TB cases), SITE-TB (TB drug resistance), and IL-TB (preventive therapy). These data were used to create a multivariable Bayesian Structural Time-Series (BSTS) model, with 5000 Monte-Carlo simulations, which identified key predictors of TB incidence and forecasted these rates from 2024 to 2030 under various scenarios.

Findings: Vulnerabilities including incarceration, TB-HIV coinfection and TB-diabetes mellitus, as well as coverages of directly observed therapy (DOT), contact investigation and preventive treatment (TPT) completion rates, were identified as key predictors of TB incidence. Under current trends, we forecasted TB incidence in Brazil to be 42.1 [34.1-49.8] per 100,000 person-years by 2030 (mean [95% prediction intervals]). A scenario considering decreases in TB cases among vulnerable populations resulted in an absolute reduction of -10.6 [-9.4 to -12.0] in projected TB incidence. Additional reductions were seen with increased coverage of DOT, TPT adherence, and contact investigation rates (-14.4 [-13 to -16.2]), and by combining these with efforts to reduce TB cases among vulnerable populations (-23.6 [-26.3 to -41.4]), potentially lowering incidence to 18.5 [7.8-28.4] per 100,000, though still above WHO targets.

Interpretation: Our findings demonstrate that interventions focused on enhancing health policies focused on decreasing TB cases among vulnerable populations, such as individuals with TB-HIV coinfection, incarcerated populations, and those with TB-diabetes comorbidity, along with improvements in health management indicators such as DOT implementation, contact investigation coverage, and TPT completion rates, are effective in reducing TB incidence nationwide.

Funding: Oswaldo Cruz Foundation.

Background: Cesarean delivery remains the most common obstetrical procedure with more than 250,000 patients in the US undergoing cesarean following labor induction annually. Here, we evaluated the impact of prospectively implementing a standardized labor induction protocol on cesarean delivery rates.

Methods: This multi-site type I hybrid effectiveness-implementation study compared 2 years before (PRE) and 2 years after (POST) implementation of a standardized labor induction protocol at two hospitals within the University of Pennsylvania Health System (2018-2022). The protocol included multiple components and recommended active management of labor induction, including frequent cervical examinations, amniotomy if cervical exam ≥4 cm, and interventions for labor dystocia. The primary effectiveness outcome was cesarean delivery. Secondary effectiveness outcomes included labor length, chorioamnionitis, and maternal and neonatal morbidity. The primary implementation outcome was fidelity, defined as adherence to ≥75% of the protocol components among 8 individual components that could be evaluated discretely. All data was collected via individual chart review.

Findings: 8509 patients were included (PRE: n = 4214, POST: n = 4295). Our population was of median age of 31 years interquartile range (IQR) [26-35], and 44.6% identified as Black, 40.1% as white, 6.9% as Asian, and 8.4% as other or unknown; 7.4% of the population identified as Latinx. There was no significant difference in cesarean delivery rate between the two time periods overall (PRE: 21.6% vs. POST: 21.8%, p = 0.85; adjusted relative risk (aRR) 0.99 95% confidence interval (CI) [0.90-1.09]). There were no significant differences in labor length, chorioamnionitis, or composite neonatal morbidity. Maternal morbidity decreased PRE to POST (PRE: 9.3% vs. POST: 6.5%, p < 0.001; aRR 0.67 95% CI [0.58-0.79]). POST-implementation, inductions with fidelity to ≥75% of protocol components increased (PRE: 52.4% vs. POST: 59.6%, p < 0.001), evidenced by more frequent cervical examinations, earlier dilation at amniotomy, and increased labor dystocia management.

Interpretation: Despite increasing standardized induction management, no significant difference in cesarean delivery was found.

Funding: NICHD K23HD102523.

Integrated programs for common mental illnesses are evidence-informed practices yet to be routinely implemented in Latin America. It synthesizes the literature on integrated programs for common mental illnesses (anxiety, depression, and posttraumatic stress disorder) in Latin American primary care and community settings. It maps program components (the 'what') to the collaborative care model core components and implementation strategies (the 'how') to the Expert Recommendations for Implementing Change (ERIC) taxonomy. Results from 18 programs across six countries (Belize, Brazil, Chile, Colombia, Mexico, Peru) show wide heterogeneity in component and strategy combinations. Overall, provider-level components and strategies were more common than family- or community-level ones. 'Team-based care' was the most commonly reported component, and 'family/user engagement' the least. The most common implementation strategy was 'supporting clinicians,' while 'changing infrastructure' was the least. Programs commonly addressed depression and only four followed experimental designs. We found limited evidence on the potential mechanisms of integrated program components and strategies.

Background: Current literature highlights a gap in precise stroke cost data for Latin America. This study measures the real costs associated with acute ischemic stroke care in Latin America using Time-Driven Activity-Based Costing (TDABC). The findings aim to lay a solid foundation for adopting value-based healthcare (VBHC) strategies in the region.

Methods: The study is an observational, multicenter, international analysis of direct costs and outcomes for patients hospitalised with acute ischemic stroke from December 2021 to December 2022. Data from stroke centres in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, Peru, and Uruguay were analysed. Costs were stratified by country. Factors such as favourable outcomes based on the modified Rankin Scale (mRS 0-2), clinical risk levels, and treatment interventions were considered for the analysis. Generalized Estimating Equation (GEE) models were utilised to assess the relationship of clinical variables with the total cost per patient.

Findings: A total of 1106 patients were included in the study. Among these patients, 74% received medical treatment alone, 18% received intravenous thrombolysis (IVT), 4% underwent mechanical thrombectomy (MT), and 3% received combined IVT plus MT. The mean cost per patient was I$ 12,203 (SD I$ 15,055), with 49% achieving a favourable functional outcome. Compared to medical treatment alone, MT incurred costs 3.1 times higher, with an incremental cost of I$ 20,418 per patient (p < 0.0001). Across all countries, costs increased according to patients' clinical risk and treatment options, with length of hospital stay emerging as the primary cost driver.

Interpretation: Our study highlights significant disparities in stroke costs across healthcare services in Latin America, influenced by variations in treatment accessibility, patient outcomes, and clinical risk profiles. These findings offer essential insights for shaping health policy decisions to enhance the long-term sustainability of stroke care in the region.

Funding: The project received funding from the World Stroke Organization and Boehringer Ingelheim (BI) IS 0135-0352.